Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Clinics in Chest Medicine

Volumn 33, Issue 1, 2012, Pages 59-68

  Kim, Dong Soon ^a  

^a University of Ulsan   (South Korea)

Author keywords

Acute exacerbation; Idiopathic pulmonary fibrosis; Incidence; Risk factors

Indexed keywords

ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA DEFENSIN; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; BOSENTAN; C REACTIVE PROTEIN; CELL PROTEIN; CYCLOSPORIN A; GAMMA1B INTERFERON; GEFITINIB; IMATINIB; INTERLEUKIN 1BETA; LACTATE DEHYDROGENASE; LEUKOCYTE ELASTASE; LIPOCORTIN 1; PEPSIN A; PIRFENIDONE; PLACEBO; POLYMYXIN B; PROTEIN ST2; SIVELESTAT; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE EXACERBATION; ACUTE RESPIRATORY FAILURE; AIR POLLUTION; BODY MASS; CAUSE OF DEATH; CIGARETTE SMOKING; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DYSPNEA; ETHNICITY; FIBROSING ALVEOLITIS; GASTROESOPHAGEAL REFLUX; HEART FAILURE; HEREDITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; HYPOXEMIA; INCIDENCE; INFECTION; INFECTIOUS PNEUMONIA; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; LUNG CANCER; LUNG LAVAGE; LUNG RESECTION; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; REVIEW; SEPSIS; SURGICAL LUNG BIOPSY;

ACUTE DISEASE; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; GASTROESOPHAGEAL REFLUX; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INCIDENCE; PNEUMONIA, ASPIRATION; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPUBLIC OF KOREA; RISK FACTORS;

EID: 84863134839     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2012.01.001     Document Type: Review

References (68)

1. Kim D.S., Collard H.R., King T.E. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006, 3(4):285-292.
2. Ley B., Collard H.R., King T.E. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 183(4):431-440.
3. Kim D.S., Park J.H., Park B.K., et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006, 27(1):143-150.
4. Kondoh Y., Taniguchi H., Kawabata Y., et al. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 1993, 103(6):1808-1812.
5. Collard H.R., Moore B.B., Flaherty K.R., et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007, 176(7):636-643.
6. Colby T.V. Interstitial disease. Atlas of pulmonary surgical pathology 1991, 227-306. WB Saunders, Philadelphia. T.V. Colby, C.M. Lombard, S.A. Yousem (Eds.).
7. Kitaichi M. Pathologic features and the classification of interstitial pneumonia of unknown etiology. Bull Chest Dis Res Inst Kyoto Univ 1990, 23(1-2):1-18.
8. Suga T., Sugiyama Y., Ohno S., et al. Nihon Kyobu Shikkan Gakkai Zasshi 1994, 32(2):174-178. [in Japanese].
9. Horio H., Nomori H., Morinaga S., et al. Nihon Kyobu Shikkan Gakkai Zasshi 1996, 34(4):439-443. [in Japanese].
10. Takahashi T., Munakata M., Ohtsuka Y., et al. Nihon Kyobu Shikkan Gakkai Zasshi 1997, 35(1):9-15. [in Japanese].
11. Martinez F.J., Safrin S., Weycker D., et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005, 142(12 Pt 1):963-967.
12. Song J.W., Hong S.B., Lim C.M., et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011, 37(2):356-363.
13. Kondoh Y., Taniguchi H., Katsuta T., et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2010, 27(2):103-110.
14. Azuma A., Nukiwa T., Tsuboi E., et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005, 171(9):1040-1047.
15. Taniguchi H., Ebina M., Kondoh Y., et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010, 35(4):821-829.
16. Noble P.W., Albera C., Bradford W.Z., et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377(9779):1760-1769.
17. Kubo H., Nakayama K., Yanai M., et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005, 128(3):1475-1482.
18. Demedts M., Behr J., Buhl R., et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005, 353(21):2229-2242.
19. Fernandez Perez E.R., Daniels C.E., Schroeder D.R., et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010, 137(1):129-137.
20. King T.E., Behr J., Brown K.K., et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008, 177(1):75-81.
21. King T.E., Brown K.K., Raghu G., et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 184(1):92-99.
22. Raghu G., Brown K.K., Costabel U., et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008, 178(9):948-955.
23. Daniels C.E., Yi E.S., Ryu J.H. Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis. Eur Respir J 2008, 32(1):170-174.
24. Daniels C.E., Lasky J.A., Limper A.H., et al. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010, 181(6):604-610.
25. King T.E., Albera C., Bradford W.Z., et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009, 374(9685):222-228.
26. Azuma A., Kudoh S. High prevalence of drug-induced pneumonia in Japan. Japan Med Assoc J 2007, 50:405-411.
27. Azuma A., Hagiwara K., Kudoh S. Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese patients. Am J Respir Crit Care Med 2008, 177(12):1397-1398. [author reply: 1398].
28. Barnes K.C. Genetic determinants and ethnic disparities in sepsis-associated acute lung injury. Proc Am Thorac Soc 2005, 2(3):195-201.
29. McMillan T.R., Moore B.B., Weinberg J.B., et al. Exacerbation of established pulmonary fibrosis in a murine model by gammaherpesvirus. Am J Respir Crit Care Med 2008, 177(7):771-780.
30. Tomioka H., Sakurai T., Hashimoto K., et al. Acute exacerbation of idiopathic pulmonary fibrosis: role of Chlamydophila pneumoniae infection. Respirology 2007, 12(5):700-706.
31. Huie T.J., Olson A.L., Cosgrove G.P., et al. A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes. Respirology 2010, 15(6):909-917.
32. Wootton S.C., Kim D.S., Kondoh Y., et al. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 183(12):1698-1702.
33. Lee J.S., Collard H.R., Raghu G., et al. Does chronic microaspiration cause idiopathic pulmonary fibrosis?. Am J Med 2010, 123(4):304-311.
34. Linden P.A., Gilbert R.J., Yeap B.Y., et al. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J Thorac Cardiovasc Surg 2006, 131(2):438-446.
35. Travis W.D., Colby T.V., Koss M.N., et al. Lipoid pneumonia and chronic fibrosis. Non-neoplastic disorders of the lower respiratory tract 2002, American Registry of Pathology and the Armed Forces Institute of Pathology, Washington, DC. D.W. King (Ed.).
36. Lee JS, Song JW, Wolters PJ, et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. ERJ Express 2011. DOI:. doi:10.1183/09031936.00050911.
37. Araya J., Kawabata Y., Jinho P., et al. Clinically occult subpleural fibrosis and acute interstitial pneumonia a precursor to idiopathic pulmonary fibrosis?. Respirology 2008, 13(3):408-412.
38. Collard H.R., Calfee C.S., Wolters P.J., et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2010, 299(1):L3-L7.
39. Konishi K., Gibson K.F., Lindell K.O., et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009, 180(2):167-175.
40. Sakamoto S., Homma S., Mun M., et al. Acute exacerbation of idiopathic interstitial pneumonia following lung surgery in 3 of 68 consecutive patients: a retrospective study. Intern Med 2011, 50(2):77-85.
41. Shintani Y., Ohta M., Iwasaki T., et al. Predictive factors for postoperative acute exacerbation of interstitial pneumonia combined with lung cancer. Gen Thorac Cardiovasc Surg 2010, 58(4):182-185.
42. Saito H., Minamiya Y., Nanjo H., et al. Pathological finding of subclinical interstitial pneumonia as a predictor of postoperative acute respiratory distress syndrome after pulmonary resection. Eur J Cardiothorac Surg 2011, 39(2):190-194.
43. Kakizaki T., Kohno M., Watanabe M., et al. Exacerbation of bleomycin-induced injury and fibrosis by pneumonectomy in the residual lung of mice. J Surg Res 2009, 154(2):336-344.
44. Kondoh Y., Taniguchi H., Kitaichi M., et al. Acute exacerbation of interstitial pneumonia following surgical lung biopsy. Respir Med 2006, 100(10):1753-1759.
45. Utz J.P., Ryu J.H., Douglas W.W., et al. High short-term mortality following lung biopsy for usual interstitial pneumonia. Eur Respir J 2001, 17(2):175-179.
46. Minegishi Y., Takenaka K., Mizutani H., et al. Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy. Intern Med 2009, 48(9):665-672.
47. Hiwatari N., Shimura S., Takishima T., et al. Bronchoalveolar lavage as a possible cause of acute exacerbation in idiopathic pulmonary fibrosis patients. Tohoku J Exp Med 1994, 174(4):379-386.
48. Yokoyama A., Kohno N., Fujino S., et al. Circulating interleukin-6 levels in patients with bronchial asthma. Am J Respir Crit Care Med 1995, 151(5):1354-1358.
49. Han W., Wang W., Mohammed K.A., et al. Alpha-defensins increase lung fibroblast proliferation and collagen synthesis via the beta-catenin signaling pathway. FEBS J 2009, 276(22):6603-6614.
50. Mukae H., Iiboshi H., Nakazato M., et al. Raised plasma concentrations of alpha-defensins in patients with idiopathic pulmonary fibrosis. Thorax 2002, 57(7):623-628.
51. Tajima S., Oshikawa K., Tominaga S., et al. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest 2003, 124(4):1206-1214.
52. Moeller A., Gilpin S.E., Ask K., et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009, 179(7):588-594.
53. Kurosu K., Takiguchi Y., Okada O., et al. Identification of annexin 1 as a novel autoantigen in acute exacerbation of idiopathic pulmonary fibrosis. J Immunol 2008, 181(1):756-767.
54. Churg A., Muller N.L., Silva C.I., et al. Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias. Am J Surg Pathol 2007, 31(2):277-284.
55. Tiitto L., Bloigu R., Heiskanen U., et al. Relationship between histopathological features and the course of idiopathic pulmonary fibrosis/usual interstitial pneumonia. Thorax 2006, 61(12):1091-1095.
56. Akira M., Kozuka T., Yamamoto S., et al. Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008, 178(4):372-378.
57. Wuyts W.A., Thomeer M., Dupont L.J., et al. An algorithm to tackle acute exacerbations in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008, 177(12):1397. [author reply: 1398].
58. Raghu G., Collard H.R., Egan J.J., ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
59. Inase N., Sawada M., Ohtani Y., et al. Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid. Intern Med 2003, 42(7):565-570.
60. Sakamoto S., Homma S., Miyamoto A., et al. Cyclosporin A in the treatment of acute exacerbation of idiopathic pulmonary fibrosis. Intern Med 2010, 49(2):109-115.
61. Seo Y., Abe S., Kurahara M., et al. Beneficial effect of polymyxin B-immobilized fiber column (PMX) hemoperfusion treatment on acute exacerbation of idiopathic pulmonary fibrosis. Intern Med 2006, 45(18):1033-1038.
62. Miyamoto K., Tasaka S., Hasegawa N., et al. Nihon Kokyuki Gakkai Zasshi 2009, 47(11):978-984. [in Japanese].
63. Nakamura M., Ogura T., Miyazawa N., et al. Nihon Kokyuki Gakkai Zasshi 2007, 45(6):455-459. [in Japanese].
64. Horita N., Akahane M., Okada Y., et al. Tacrolimus and steroid treatment for acute exacerbation of idiopathic pulmonary fibrosis. Intern Med 2011, 50(3):189-195.
65. Park I.N., Kim D.S., Shim T.S., et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest 2007, 132(1):214-220.
66. Suda T., Kaida Y., Nakamura Y., et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir Med 2009, 103(6):846-853.
67. Akira M., Sakatani M., Hara H. Thin-section CT findings in rheumatoid arthritis-associated lung disease: CT patterns and their courses. J Comput Assist Tomogr 1999, 23(6):941-948.
68. Dawson J.K., Fewins H.E., Desmond J., et al. Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann Rheum Dis 2002, 61(6):517-521.